Stay updated on Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedNIH grant year notes for 2016 and 2023 were added. The page revision label was updated to v3.6.6, replacing the previous v3.6.5.SummaryDifference0.2%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedData-sharing and sponsor sections were added, including an IPD Sharing URL and IPD Plan Description. A PDF link for the Study Protocol and SAP was included, and PubMed references with MeSH terms were updated to provide broader context.SummaryDifference67%

- Check37 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, indicating a minor backend/documentation update to the study record.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page now displays Revision: v3.6.4, replacing the previous Revision: v3.6.3. This reflects a software/version update to the site rather than a change to study content.SummaryDifference0.0%

- Check73 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous v3.6.2, indicating an updated page build. This reflects an internal update or bug fix rather than substantive changes to the study information.SummaryDifference0.0%

- Check80 days agoChange DetectedA new revision label (v3.6.2) has been added, replacing the previous v3.6.0. This reflects a minor maintenance update to the page or its underlying documentation rather than a change to study details or user-facing features.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.